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The response rate was 51.2% (95% CI, 35.1%--67.1%) in the S‐1--cisplatin group and 53.5% (95% CI, 37.7%--68.8%) in the capecitabine‐cisplatin group (*p* \> .999). The DCR for the FAS was higher in the S‐1--cisplatin arm (82.9%) than in the capecitabine‐cisplatin arm (67.4%). A waterfall plot analysis revealed that patients in the S‐1--cisplatin arm showed greater tumor shrinkage and that a larger proportion of patients in this arm experienced tumor shrinkage from baseline compared with the capecitabine‐cisplatin arm (Fig. [1](#onco12632-fig-0001){ref-type="fig"}).

![Waterfall plot of maximum percentage change in target lesion size according to RECIST. S‐1--cisplatin **(A)** and capecitabine‐cisplatin **(B)** groups, respectively.](onco12632-fig-0001){#onco12632-fig-0001}

For survival analysis, the median follow‐up time was 11.3 months. The median PFS was 5.9 months in the S‐1--cisplatin group and 4.1 months in the capecitabine‐cisplatin group (HR, 0.763; 95% CI, 0.462--1.259; *p* = .284) (Fig. [2](#onco12632-fig-0002){ref-type="fig"}A), whereas the corresponding values for median OS were 13.5 and 10.0 months (HR, 0.776; 95% CI, 0.485--1.244; *p* = .290) (Fig. [2](#onco12632-fig-0002){ref-type="fig"}B) and those for median TTF were 4.5 and 3.1 months (HR, 0.651; 95% CI, 0.421--1.006; *p* = .052) (Fig. [2](#onco12632-fig-0002){ref-type="fig"}C).

![Kaplan‐Meier estimates of survival. PFS **(A)**, OS **(B)**, and TTF **(C)**. Red and green lines indicate S‐1--cisplatin (SP) and capecitabine‐cisplatin (XP) groups, respectively.\
Abbreviations: OS, overall survival; PFS, progression‐free survival; TTF, time to treatment failure.](onco12632-fig-0002){#onco12632-fig-0002}

The most common all‐grade hematologic adverse events were anemia (79% in the S‐1--cisplatin group, 74% in the capecitabine‐cisplatin group) and neutropenia (54% and 60%), each of which occurred at a similar frequency in the two groups. In contrast, anemia and neutropenia of grade 3 or 4 were more common in the capecitabine‐cisplatin group than in the S‐1--cisplatin group. With regard to nonhematologic toxicities, anorexia (67% and 72%) and malaise (46% and 49%) were common all‐grade adverse events in both treatment groups. Anorexia, fatigue, and hyponatremia of grade 3 or 4 were more frequent in the capecitabine‐cisplatin group (23%, 14%, and 16%) than in the S‐1--cisplatin group (13%, 0%, and 5%). Peripheral neuropathy and hand‐foot syndrome of grade 3 or 4 were apparent in the capecitabine‐cisplatin arm (5% and 2%) but not in the S‐1--cisplatin arm. One death in the capecitabine‐cisplatin group (2%, 1 of 43) was due to brain infarction, which was considered to be treatment related by the investigators.
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**Disease**Gastric cancer**Stage of Disease/Treatment**Metastatic/advanced**Prior Therapy**None**Type of Study -- 1**Phase II**Type of Study -- 2**Randomized**Primary Endpoint**Overall response rate**Secondary Endpoint**Progression‐free survival**Secondary Endpoint**Overall survival**Secondary Endpoint**Safety**Secondary Endpoint**Time to treatment failure**Additional Details of Endpoints or Study Design** The trial was based on a randomized phase II screening design with a primary endpoint of response rate (RR). On the basis of an assumed RR of 40% in the S‐1‐cisplatin arm, the study was designed to detect an improvement in RR of 15 percentage points (i.e., to 55%) in the capecitabine‐cisplatin arm. For primary analysis, 100 patients were required to detect such an improvement in RR with ≥80% power, with a one‐sided significance level of 0.20 in Fisher's exact test. However, as a result of slow accrual, the protocol was amended in December 2015 to reduce the planned sample size from 100 to 84 based on a one‐sided significance level of 0.10 and power of 70%. Ultimately, enrollment was terminated after inclusion of 85 patients in April 2016. The primary endpoint of the study was RR, with secondary end points including PFS, OS, TTF, and safety. Tumor response was assessed by investigators on the basis of RECIST version 1.1 at baseline and every 8 weeks after randomization until disease progression. The RR and disease control rate were defined as the proportion of patients who achieved a confirmed complete response (CR) or partial response (PR) or who achieved a confirmed CR, PR, or stable disease (SD), respectively. Tumor histology was based on the Japanese classification of gastric carcinoma, with differentiated‐type tumors being defined as papillary or tubular adenocarcinoma and undifferentiated‐type tumors as poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous adenocarcinoma. Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. **Investigator's Analysis** Inactive because results did not meet primary endpoint 

Drug Information for Phase II S‐1 + CDDP {#onco12632-sec-1006}
========================================

Drug 1 Generic/Working NameS‐1Trade NameTS‐1Company NameTaiho Pharmaceutical, Co, Ltd.Dose80--120 mg/m^2^Routep.o.Schedule of AdministrationS‐1 at 40--60 mg twice daily for 21 days every 5 weeksDrug 2 Generic/Working NameCisplatin (CDDP)Drug ClassPlatinum compoundDose60 mg/m^2^RouteIVSchedule of AdministrationCisplatin at 60 mg/m^2^ on day 8, every 5 weeks

Drug Information for Phase II Capecitabine + CDDP {#onco12632-sec-1008}
=================================================

Drug 1 Generic/Working NameCapecitabineTrade NameXelodaCompany NameChugai Pharmaceutical, Co, Ltd.Dose2,000 mg/m^2^Routep.o.Schedule of AdministrationCapecitabine at 1,000 mg/m^2^ twice daily for 14 days every 3 weeksDrug 2 Generic/Working NameCisplatin (CDDP)Drug ClassPlatinum compoundDose80 mg/m^2^RouteIVSchedule of AdministrationCisplatin at 80 mg/m^2^ on day 1 every 3 weeks
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Primary Assessment Method for Phase II S‐1 + CDDP {#onco12632-sec-1056}
=================================================

TitleTotal patient populationNumber of Patients Screened41Number of Patients Enrolled39Number of Patients Evaluable for Toxicity39Number of Patients Evaluated for Efficacy41Evaluation MethodRECIST 1.1Response Assessment CR*n* = 0 (0%)Response Assessment PR*n* = 21 (51%)Response Assessment SD*n* = 13 (32%)Response Assessment PD*n* = 3 (7%)Response Assessment OTHER*n* = 4 (10%)(Median) Duration Assessments PFS179 days, confidence interval (CI): 136--225(Median) Duration Assessments OS412 days, CI: 340--701

Secondary Assessment Method for Phase II S‐1 + CDDP {#onco12632-sec-1030}
===================================================

TitleTotal patient population(Median) Duration Assessments PFS179 days, CI: 136--225(Median) Duration Assessments OS412 days, CI: 340--701

Primary Assessment Method for Phase II Capecitabine + CDDP {#onco12632-sec-1025}
==========================================================

TitleTotal patient populationNumber of Patients Screened43Number of Patients Enrolled43Number of Patients Evaluable for Toxicity43Number of Patients Evaluated for Efficacy43Evaluation MethodRECIST 1.1Response Assessment CR*n* = 0 (0%)Response Assessment PR*n* = 23 (53%)Response Assessment SD*n* = 6 (14%)Response Assessment PD*n* = 10 (3%)Response Assessment OTHER*n* = 4 (10%)(Median) Duration Assessments PFS124 days, CI: 108--200(Median) Duration Assessments OS305 days, CI: 218--474
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============================================================

TitleTotal patient population(Median) Duration Assessments PFS124 days, CI: 108--200(Median) Duration Assessments OS305 days, CI: 218--474
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Serious Adverse Events {#onco12632-sec-3006}
======================
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Assessment, Analysis, and Discussion {#onco12632-sec-2006}
====================================

CompletionStudy completedInvestigator\'s AssessmentInactive because results did not meet primary endpoint

 {#onco12632-sec-8006}

Gastric cancer is the fifth most common malignant disease and the second leading cause of cancer deaths worldwide \[[1](#onco12632-bib-0001){ref-type="ref"}\], with an especially high incidence in East Asia. Individuals newly diagnosed with gastric cancer often present with unresectable or metastatic disease, known as advanced gastric cancer (AGC). Trastuzumab in combination with chemotherapy has been found to confer a significantly better overall survival (OS) compared with chemotherapy alone in patients with AGC positive for human epidermal growth receptor 2 (HER2) \[[2](#onco12632-bib-0002){ref-type="ref"}\]. On the other hand, for individuals with HER2‐negative disease, who account for most cases of AGC, treatment options are largely restricted to conventional therapy such as doublet or triplet combination chemotherapy. The outcome for such patients thus remains poor, with a global standard regimen for treatment of HER2‐negative AGC remaining to be established.

In East Asia, including Japan and Korea, the combination of a fluoropyrimidine plus a platinum agent has been adopted as standard therapy for HER2‐negative AGC \[[3](#onco12632-bib-0003){ref-type="ref"}\], \[[4](#onco12632-bib-0004){ref-type="ref"}\]. S‐1 is a fluoropyrimidine preparation that includes tegafur, gimeracil, and oteracil potassium in a molar ratio of 1:0.4:1 and was designed to minimize gastrointestinal toxicity and maximize antitumor activity \[[5](#onco12632-bib-0005){ref-type="ref"}\]. The SPIRITS phase III trial showed that S‐1 in combination with cisplatin conferred a significant survival benefit (median survival time of 13.1 months) compared with S‐1 alone, resulting in this combination being accepted as a standard first‐line regimen for AGC in East Asia \[[3](#onco12632-bib-0003){ref-type="ref"}\]. In Western countries, regimens containing a fluoropyrimidine plus a platinum compound and either docetaxel \[[6](#onco12632-bib-0006){ref-type="ref"}\] or epirubicin \[[7](#onco12632-bib-0007){ref-type="ref"}\] have improved survival in patients with AGC. However, the combination of a fluoropyrimidine plus a platinum agent has been widely accepted as a standard treatment option for such patients in practice, given that the addition of docetaxel or epirubicin was associated with a limited improvement in survival but substantial hematologic toxicity \[[6](#onco12632-bib-0006){ref-type="ref"}\], \[[7](#onco12632-bib-0007){ref-type="ref"}\].

Capecitabine is an oral fluoropyrimidine prodrug that manifests high antitumor activity in association with low toxicity, given that it is converted to 5‐fluorouracil (5‐FU) by thymidine phosphorylase, which is present at much higher concentrations in tumor cells than in normal cells \[[8](#onco12632-bib-0008){ref-type="ref"}\]. As capecitabine plus cisplatin was found to be noninferior to 5‐FU plus cisplatin in terms of progression‐free survival (PFS) for the first‐line treatment of AGC, the former combination is now considered an effective alternative to the latter \[[4](#onco12632-bib-0004){ref-type="ref"}\]. Moreover, capecitabine‐cisplatin has been adopted as a standard backbone chemotherapy for combination with trastuzumab \[[2](#onco12632-bib-0002){ref-type="ref"}\] or other molecularly targeted agents such as bevacizumab \[[9](#onco12632-bib-0009){ref-type="ref"}\] or cetuximab \[[10](#onco12632-bib-0010){ref-type="ref"}\] in global phase III trials for AGC.

In Japan, capecitabine was approved for AGC in 2011, and the safety and efficacy of capecitabine‐cisplatin in the Japanese population have been demonstrated in two global phase III trials---the AVAGAST \[[9](#onco12632-bib-0009){ref-type="ref"}\] and ToGA \[[2](#onco12632-bib-0002){ref-type="ref"}\] studies---in which 94 Japanese AGC patients of unknown HER2 status and 50 Japanese patients with HER2‐positive AGC, respectively, received this combination alone \[[11](#onco12632-bib-0011){ref-type="ref"}\]. In these two studies, the median OS, median PFS, and overall response rate (RR) were 14.2--17.7 months, 5.6--5.7 months, and 49.2%--58.5%, respectively. Adverse events were generally mild, with the most common events of grade 3 or 4 being neutropenia, anemia, anorexia, and nausea. Similar efficacy and safety profiles for capecitabine‐cisplatin in Japanese AGC patients were also apparent in a retrospective study \[[12](#onco12632-bib-0012){ref-type="ref"}\]. These data have suggested that capecitabine‐cisplatin is similar or possibly superior to S‐1‐cisplatin in terms of safety and efficacy for Japanese patients with AGC. However, capecitabine‐cisplatin has not been prospectively compared with S‐1‐cisplatin in patients with HER2‐negative AGC to date. We have therefore now conducted a phase II study to assess the efficacy and safety of capecitabine‐cisplatin versus S‐1‐cisplatin in Japanese patients with HER2‐negative AGC.

In our trial, however, capecitabine‐cisplatin failed to show a superior efficacy relative to S‐1‐cisplatin. Although RR, the primary endpoint of our trial, did not differ significantly between the two treatment groups, disease control rate (DCR) was higher in the S‐1‐cisplatin arm, with this benefit being confirmed by waterfall analysis. The benefit of S‐1‐cisplatin with regard to its high DCR likely reflects the observed trend toward a better PFS and OS in the S‐1‐cisplatin arm than in the capecitabine‐cisplatin arm.

With respect to adverse events, both regimens in the present study showed similar hematologic toxicity profiles, with anemia and neutropenia being most frequently observed. In contrast, the overall incidence of nonhematologic toxicities of grade 3 or 4 was higher in the capecitabine‐cisplatin group than in the S‐1‐cisplatin group. A meta‐analysis comparing S‐1 with capecitabine in AGC found no overall difference in terms of serious adverse events \[[13](#onco12632-bib-0013){ref-type="ref"}\]. In the present study, however, anorexia, fatigue, and hyponatremia of grade 3 or 4 occurred more frequently in the capecitabine‐cisplatin arm than in the S‐1‐cisplatin arm. Moreover, brain infarction of grade 5 occurred in one patient of the capecitabine‐cisplatin group, possibly as a result of the high dose intensity of cisplatin, which is known to be associated with venous thromboembolism \[[14](#onco12632-bib-0014){ref-type="ref"}\]. Indeed, most of the differences in nonhematologic toxicity between the two groups were likely due to the higher dose of cisplatin administered in the capecitabine‐cisplatin arm, which was also associated with a shorter time to treatment failure. Together, our findings suggest that, at least in the setting of the present trial, administration of cisplatin at 80 mg/m^2^ every 3 weeks in combination with capecitabine did not increase efficacy but was more toxic compared with that at 60 mg/m^2^ every 5 weeks in combination with S‐1.

In conclusion, although our study was a phase II trial and our results thus need confirmation, capecitabine‐cisplatin failed to demonstrate superior efficacy over S‐1‐cisplatin. The higher incidence of severe nonhematologic adverse events observed with capecitabine‐cisplatin suggests that S‐1‐cisplatin should remain the standard first‐line chemotherapy for HER2‐negative AGC with measurable lesions, at least in Japan.
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